Principal Investigator
Matthew Schlumbrecht
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20241077
Clinical Trial Summary
REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants with Advanced/Metastatic Solid Tumors
Phase
Phase II
Funding Agency/Sponsor
Industrial
Disease
Gynecologic Cancer
Contact Information
Phone Number
305-243-2647